Orthofix Medical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OFIX research report →
Range $9 – $15
Price Chart
About the company
Orthofix Medical Inc. , founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets.
- CEO
- Massimo Calafiore
- IPO
- 1992
- Employees
- 1,605
- HQ
- Lewisville, TX, US
Get TickerSpark's AI analysis on OFIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $247.41M
- P/E
- -5.98
- PEG
- -0.06
- P/S
- 0.33
- P/B
- 0.64
- EV/EBITDA
- 4.41
- Div Yield
- 0.00%
- Gross Margin
- 69.17%
- Op Margin
- -0.65%
- Net Margin
- -5.39%
- ROE
- -10.32%
- ROIC
- -0.76%
Latest fiscal year · YoY change
- Revenue
- $822.31M+2.9%
- Gross Profit
- $551.71M+1.1%
- Op Income
- $-68,471,000
- Net Income
- $-92,192,000+26.8%
- EPS
- $-2.28+30.9%
- OCF Growth
- +29.3%
- FCF Growth
- +85.9%
- 52W High
- $16.42
- 52W Low
- $6.03
- 50D MA
- $8.88
- 200D MA
- $10.69
- Beta
- 0.64
- RSI (14)
- 26
- Avg Volume
- 480.60K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Orthofix said Q3 results were below plan, with Spine pressure and supplier delays offsetting strength in limb reconstruction, Therapeutic Solutions, and stabilizing Biologics.· November 9, 2026
- Q3 net sales were $207.9 million, up 2.3% year over year on a reported basis.
- Non-GAAP adjusted gross margin was 70.7%, and adjusted EBITDA was $26 million, or 12.5% of pro forma net sales, versus $24.6 million and 12.1% a year ago.
- Global Limb Reconstruction grew 9% constant currency to $36.4 million, with FITBONE and TrueLok Elevate each growing more than 20%.
- Therapeutic Solutions posted $64 million of sales, up 4%, while Biologics was roughly flat sequentially and returned to positive year-over-year growth in October.
- Management lowered full-year 2026 outlook to $825 million-$830 million in pro forma net sales and $86 million-$88 million in adjusted EBITDA, citing Spine softness, supplier issues, order timing and FX.
Third-quarter reported net sales were $207.9 million, up 2.3% year over year. On a pro forma constant-currency basis excluding discontinued M6 product lines, Global Spinal Implants, Biologics and Enabling Technologies generated $107.4 million, down about 1%; Therapeutic Solutions generated $64 million, up 4%; and Global Limb Reconstruction delivered $36.4 million, up 9%. Non-GAAP adjusted gross margin was 70.7%, and adjusted EBITDA was $26 million, or 12.5% of pro forma net sales, versus $24.6 million, or 12.1%, in the prior-year period. The company ended the quarter with $86.9 million in cash, cash equivalents and restricted cash. For full-year 2026, management now expects pro forma net sales of $825 million to $830 million and non-GAAP adjusted EBITDA of $86 million to $88 million. The revised outlook reflects third-quarter performance, continued Spine softness, accelerated actions to improve U.S. Spine execution and inventory availability, timing of international limb reconstruction orders, and foreign exchange headwinds. Management also said most of the approximately $15 million 2026 net sales benefit from the European distributor arrangement should be recognized in Q4, while the European MDR strategy for Spine is expected to create an approximately $22 million net sales headwind in 2027.
Massimo Calafiore said the quarter was weaker than expected, mainly because of market softness in Spine and unplanned supplier delays that created inventory and instrument-set constraints. He emphasized that the company is concentrating resources behind core distributors and higher-value products, simplifying the portfolio, and prioritizing VIRATA and 7D. His tone was cautious on the near term but constructive on the path into 2027, repeatedly saying the strategy is unchanged and that the company expects to be better positioned after the current transition.
Julie Andrews walked through the quarter’s financials and noted that the business mix and Spine weakness pressured results, while cost discipline helped support profitability. She highlighted the 70.7% adjusted gross margin, $26 million of adjusted EBITDA, and $86.9 million of ending cash, saying cash usage was driven mainly by working capital timing, investment in instrument sets ahead of VIRATA, and inventory for the European MDR strategy. She also pointed to the updated 2026 guide of $825 million to $830 million in net sales and $86 million to $88 million in adjusted EBITDA, with Q4 benefiting from seasonality and the European distributor arrangement but also facing supplier, market, timing and FX headwinds.
Analysts focused on whether Spine weakness reflected market softness or market-share loss, and management said it looked more like softer procedural demand plus temporary supply-chain disruptions, not a broad share problem. Asked about 2027, management said limb reconstruction and Therapeutic Solutions should remain above-market, and that core revenue should be positive after backing out the MDR impact, with a full quarter of VIRATA in Q1 2027. When pressed on distributor growth, Julie Andrews said core distributor growth slowed to the mid-single digits, and management also said the company is not yet committing to a longer-term financial target or an LRP timeline.
The bull case from the call is that Orthofix has visible growth engines outside Spine: limb reconstruction grew 9% constant currency, FITBONE and TrueLok Elevate each grew more than 20%, and Therapeutic Solutions grew 4% with strong margins and cash generation. Management also described Biologics as stabilizing and said October was positive year over year, while VIRATA remains on track for a Q4 launch and 7D continues to advance through new 510(k) clearances.
The bear case is that Spine remains under pressure from market softness, supplier delays, and temporary inventory/instrument constraints, forcing a full-year revenue and EBITDA cut. Management also warned that the European MDR strategy will create an approximately $22 million net sales headwind in 2027, and that the European distributor arrangement creates a 2026 cash timing headwind. Even with optimism about 2027, management did not give detailed 2027 guidance or a longer-term target reset.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 40.76M
- Float Shares
- 40.44M
of shares held by institutions
142 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Engine Capital Management, LP | 4.58M | ▲ 184.90K |
| Juniper Investment Company, LLC | 4.44M | ▲ 465.58K |
| Blackrock, Inc. | 3.86M | ▲ 536.77K |
| Rubric Capital Management LP | 3.72M | 0 |
| Paradigm Capital Management Inc/Ny | 3.29M | ▼ 6.60K |
| Armistice Capital, LLC | 3.26M | ▲ 564.00K |
| Vanguard Group Inc | 2.30M | ▲ 22.26K |
| Vanguard Capital Management LLC | 1.70M | ▼ 28.41K |
| State Street Corp | 1.00M | ▲ 48.40K |
| Geode Capital Management, LLC | 925.35K | ▼ 122.73K |
| Aqr Capital Management LLC | 887.28K | ▲ 698.16K |
| Millennium Management LLC | 862.03K | ▼ 204.87K |
Held by 196 ETFs
Biggest fund positions in OFIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Juniper Investment Company, LLC | buy | 14,803 |
| Nov 9, 26 | Juniper Investment Company, LLC | buy | 675,000 |
| Nov 2, 26 | Fisher Patrick | sell | 150 |
| Oct 1, 26 | Fisher Patrick | sell | 150 |
| Sep 21, 26 | Juniper Investment Company, LLC | buy | 190,000 |
| Sep 18, 26 | Juniper Investment Company, LLC | buy | 120,000 |
| Sep 21, 26 | Juniper Investment Company, LLC | sell | 190,000 |
| Sep 18, 26 | Juniper Investment Company, LLC | sell | 120,000 |
| Sep 1, 26 | Fisher Patrick | sell | 150 |
| Aug 18, 26 | Fisher Patrick | sell | 1,295 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OFIX coverage
Recent articles, reports, and earnings notes.
No research on OFIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OFIX report →Orthofix (OFIX) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Nov 18
Orthofix Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 9
Orthofix Medical Inc. (OFIX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Orthofix (OFIX) Surpasses Q3 Earnings Estimates
zacks.com · Nov 9
Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance
businesswire.com · Nov 9
Orthofix (OFIX) Surges 11.0%: Is This an Indication of Further Gains?
zacks.com · Nov 5
Orthofix to Report Third Quarter 2026 Financial Results
businesswire.com · Oct 23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)
prnewswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.